Asset
PEGUNIGALSIDASE ALFA
PROTALIX BIOTHERAPEUTICS INC. (DE) COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01678898 | phase1_2 | completed | 2012-10-01 | 2016-03-06 | Protalix | Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients |
| NCT01981720 | phase1_2 | completed | 2014-01-16 | 2020-08-26 | Protalix | Extension Study of PRX-102 for up to 60 Months |
| NCT03018730 | phase3 | completed | 2017-05-17 | 2019-12-17 | Protalix | Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa) |
| NCT03180840 | phase3 | completed | 2017-07-10 | 2020-08-01 | Protalix | Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks |
| NCT02795676 | phase3 | completed | 2016-06-01 | 2021-10-01 | Protalix | Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function |
FDA applications (0)
This company has no applications containing this asset.